Sun Pharma said on Saturday that they are acquiring 100% Innovcare Lifesciences for ₹271.2 crore ($28.7 million). This was a very big move by Sun Pharma to expand its presence in wellness and nutraceutical markets. The pharmaceutical major signed a definitive agreement to purchase all outstanding shares in an all-cash transaction, with the deal expected to close on or before July 31, 2026. Founded in July 2014, Mumbai-based Innovcare specialises in manufacturing and marketing nutraceuticals, lifestyle wellness, and cosmeceutical products within the domestic Indian healthcare market.
This acquisition has helped Sun Pharma to broaden the drug market, especially in the well-growing sectors like orthopaedics and gynaecology. Meanwhile, Innovcare has been making steady money over the last few years. Its sales grew from ₹80.93 crore in 2023-24 to ₹86.09 crore in 2024-25 and reached ₹94.06 crore in 2025-26.
This investment aligns with a major trend in which big drug companies use their strong financial position to grow their sales at home, protecting themselves from price changes in global markets. In the end, buying Innovcare’s products helps Sun Pharma gain a bigger share of the preventive healthcare market. Sun Pharma has acquired many big companies and has become one of the top pharma companies in India and the largest global company.
Furthermore, this acquisition highlights the increasing consolidation within the Indian healthcare space, as major pharmaceutical firms look to absorb niche brands that have built strong consumer loyalty. By using Innovcare’s existing factories, suppliers, and sales teams, Sun Pharma can quickly sell these new products through its own huge network of shops and pharmacies. This strategy allows the company to immediately boost its market share in the premium consumer healthcare sector without having to spend years developing new brands from scratch.
